KMPH VS CYTO Stock Comparison
Performance
KMPH100/100
100/100
KMPH returned 1.93% in the last 12 months. Based on the other stocks in it's sector with an average return of -26.16%, it's performance is above average giving it a grade of 100 of 100.
CYTO10/100
10/100
CYTO returned -98.21% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Forecast
KMPH85/100
85/100
5 analysts offer 12-month price forecasts for KMPH. Together, they have an average target of 10, the most optimistic forecast put KMPH at 10 within 12-months and the most pessimistic has KMPH at 10.
CYTO
"Forecast" not found for CYTO
Sentiment
KMPH71/100
71/100
KMPH had a bullish sentiment score of 70.75% across Twitter and StockTwits over the last 12 months. It had an average of 74.19 posts, 109.25 comments, and 291.58 likes per day.
CYTO
"Sentiment" not found for CYTO
Technicals
KMPH93/100
93/100
KMPH receieves a 92 of 100 based on 14 indicators. 12 are bullish, 0 are bearish.
CYTO14/100
14/100
CYTO receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
KMPH10/100
10/100
KMPH has missed earnings 9 times in the last 20 quarters.
CYTO44/100
44/100
CYTO has missed earnings 2 times in the last 20 quarters.
Profit
KMPH21/100
21/100
Out of the last 20 quarters, KMPH has had 4 profitable quarters and has increased their profits year over year on 3 of them.
CYTO13/100
13/100
Out of the last 20 quarters, CYTO has had 2 profitable quarters and has increased their profits year over year on 2 of them.
Volatility
KMPH55/100
55/100
KMPH has had a higher than average amount of volatility over the last 12 months giving it a grade of 55 of 100.
CYTO25/100
25/100
CYTO has had a lower than average amount of volatility over the last 12 months giving it a score of 25 of 100.
Dividend
KMPH10/100
10/100
KMPH has not paid a dividend in the last 5 years.
CYTO
"Dividend" not found for CYTO
All score calculations are broken down here to help you make more informed investing decisions
KemPharm, Inc. Common Stock Summary
Nasdaq / KMPH
Healthcare
Biotechnology
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.
Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) Summary
Nasdaq / CYTO
Healthcare
Biotechnology
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare KMPH to other companies in the same or a similar industry.